Sanofi-a Ventis Deutschland Gmbh

Sanofi-aventis

Aventis Pharma Deutschland, Gmbh

Sanofi

Aventis Pharma S.a.

Karl Schoenafinger

Elisabeth Defossa

Hans Matter

Gerhard Jaehne

Dieter Kadereit

Andreas W Herling

Georg Tschank

Christian Buning

Ulrich Werner

Thomas Klabunde

Karl-Ulrich Wendt

Hartmut Strobel

Stefanie Keil

Uwe Heinelt

Wolfgang Wendler

Matthias Urmann

Henning Steinhagen

Maike Glien

Matthias Herrmann

Volkmar Wehner

David William Will

Ursula Schindler

Guenter Mueller

Stefan Petry

Alfons Enhsen

Martin Bossart

Hans-Ludwig Schaefer

Eugen Falk

Karl-Heinz Baringhaus

Gunter Muller

Lothar Schwink

Hubert Heuer

Paulus Wohlfart

Armin Walser

Jacques Mauger

Pavel Safar

Hans-Joerg Burger

Erich Von Roedern

Swen Hoelder

Anke Steinmetz

Ingrid Sassoon

Holger Wagner

Christine Delaisi

Bodo Scheiper

Cecile Combeau

Didier Benard

Holger Gaul

Alena Safarova

Guenter Billen

Armin Bauer

Joerg Rieke-Zapp

Ramalinga M Dharanipragada

Axel Dietrich

Günter Müller

Teri Suzuki

Dieter Schmoll

Johanna Kuhlmann-Gottke

Cécile Combeau

Karl-Christian Engel

Viola Groehn

Ursula Schnidler

Elisabeth DeFossa

Thomas Kalbunde

Axel Deitrich

Volkmar Herrmann

Ulrike Wendler, Legal Representative

Johanna Kuhlmann

Hubert Otto Heuer

Erich Von Reodern

Karl-Urlich Wendt

Elizabeth Defossa

Christian Bunning

The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.

Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments

This disclosure relates to compounds of formula I: wherein R1, R2, R3, R4, X and Y have the meanings denoted in the disclosure. The compounds of formula I have antithrombotic activity and in particular inhibit the protease-activated receptor 1 (PAR1). The disclosure further relates to a method for producing the compound of formula I and to the use thereof as a pharmaceutical product.

Tricyclic pyridyl-vinyl pyrroles as PAR1 inhibitors

The invention relates to novel compounds of formula I where X, A, Q1, Q2, Q3, R2, R3, R4, R5, R6, R7, R8 and R9 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.

Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments

The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, R9, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.

Imidazopyridazines as PAR1 inhibitors, production thereof, and use as medicaments

The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R9, Ar, Q1, Q2 and Q3 are each as defined below. The compounds of the formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of the formula I and to the use thereof as a medicament.

[object Object]

The invention relates to cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals

The invention relates to urea- and urethane-substituted acylureas and to their physiologically tolerated salts and physiologically functional derivatives. In particular, the invention relates to the compounds of the formula I wherein the radicals have meanings described herein, and to their physiologically tolerated salts and to processes for their preparation. The compounds are suitable for example as antidiabetics.

Urea- and urethane-substituted acylureas, process for their preparation and their use

The invention 8-aminothioxanthines and the derivatives of formula I wherein the various R groups and substituents are comprised of a number of different (C-C)-alkyl, cycloalkyl, aryl, alkene, alkyne, etc. groups and derivatives thereof which are hereinafter more specifically defined for the treatment of metabolic disorders such as type-2 diabetes, hyperglycemia, arteriosclerotic diseases and the like.

Substituted 8-aminoalkylthioxanthines, and their use as inhibitors of dipeptidyl peptidase IV

The invention relates to sulfonyl-phenyl-oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What are described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals

The present invention comprises the use of amino-substituted 8-N-benzimidazoles compounds of formula I wherein R3, R4-R5, R11 and R20-R21 are hereinafter defined which display a therapeutically utilizable blood sugar-lowering action. These compounds are intended to be particularly suitable in the treatment of diabetes.

Amide-substituted 8-N-benzimidazoles, method for the production thereof, and use of the same as medicaments

The present invention comprises the use of amino-carbonyl-substituted 8-N-benzimidazoles compounds of formula I wherein R3, R4-R5, R11 and R20-R21 are hereinafter defined which display a therapeutically utilizable blood sugar-lowering action. These compounds are intended to be particularly suitable in the treatment of diabetes, carbohydrate and lipid metabolic disorders and other blood sugar complications.

Aminocarbonyl-substituted 8-N-benzimidazoles, methods for their preparation and their use in pharmaceutical compositions

Amino-substituted 8-N-benzimidazoles and methods for their use in blood sugar disorders

Disclosed are compounds of Formula I wherein X is and R, R, A, B, D, E, Rare as defined herein useful for treating cancers.

Pyridazinone kinase inhibitors

Growing community of inventors

Alzenau, Germany

Karl Schoenafinger